REGENXBIO Yönetim
Yönetim kriter kontrolleri 3/4
REGENXBIO CEO'su Curran Simpson, Jul2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 2.95M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.4% maaş ve 82.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.031% ine doğrudan sahiptir ve bu hisseler $ 134.52K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.9 yıl ve 7.4 yıldır.
Anahtar bilgiler
Curran Simpson
İcra Kurulu Başkanı
US$3.0m
Toplam tazminat
| CEO maaş yüzdesi | 17.4% |
| CEO görev süresi | less than a year |
| CEO sahipliği | 0.03% |
| Yönetim ortalama görev süresi | 5.9yrs |
| Yönetim Kurulu ortalama görev süresi | 7.4yrs |
Son yönetim güncellemeleri
Recent updates
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Oct 31Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Sep 12
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Aug 06REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
Jul 26Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$241m |
| Mar 31 2024 | n/a | n/a | -US$260m |
| Dec 31 2023 | US$3m | US$513k | -US$263m |
| Sep 30 2023 | n/a | n/a | -US$261m |
| Jun 30 2023 | n/a | n/a | -US$274m |
| Mar 31 2023 | n/a | n/a | -US$270m |
| Dec 31 2022 | US$2m | US$475k | -US$280m |
| Sep 30 2022 | n/a | n/a | US$74m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$101m |
| Dec 31 2021 | US$3m | US$448k | US$128m |
| Sep 30 2021 | n/a | n/a | -US$212m |
| Jun 30 2021 | n/a | n/a | -US$145m |
| Mar 31 2021 | n/a | n/a | -US$121m |
| Dec 31 2020 | US$2m | US$428k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$91m |
| Jun 30 2020 | n/a | n/a | -US$135m |
| Mar 31 2020 | n/a | n/a | -US$103m |
| Dec 31 2019 | US$2m | US$382k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$64m |
| Jun 30 2019 | n/a | n/a | -US$49m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$2m | US$371k | US$100m |
| Sep 30 2018 | n/a | n/a | US$80m |
| Jun 30 2018 | n/a | n/a | US$78m |
| Mar 31 2018 | n/a | n/a | US$53m |
| Dec 31 2017 | US$912k | US$361k | -US$73m |
Tazminat ve Piyasa: Curran 'ın toplam tazminatı ($USD 2.95M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.40M ).
Tazminat ve Kazançlar: Curran şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Curran Simpson (62 yo)
less than a year
Görev süresi
US$2,950,002
Tazminat
Mr. Curran M. Simpson, M.S., had been the Chief Operating Officer at REGENXBIO Inc. since January 2023 until July 01, 2024 and served as its Executive Vice President until July 01, 2024 and serves as its P...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | less than a year | US$2.95m | 0.031% $ 134.5k | |
| Executive VP & Chief Scientific Officer | 7.7yrs | US$2.99m | 0.061% $ 263.3k | |
| Advisor | less than a year | US$2.62m | 0.38% $ 1.6m | |
| Executive VP & Chief Medical Officer | 5.6yrs | US$3.31m | 0% $ 0 | |
| Executive VP & CFO | less than a year | Veri yok | Veri yok | |
| Executive VP & Chief Legal Officer | 8.3yrs | US$3.44m | 0.046% $ 199.6k | |
| Chief Communications & People Officer | 7.1yrs | Veri yok | Veri yok | |
| Executive VP of Commercial Strategy & Operations | 6.3yrs | Veri yok | Veri yok |
5.9yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: RGNX 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.9 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | less than a year | US$2.95m | 0.031% $ 134.5k | |
| Independent Director | 9.1yrs | US$339.98k | 0.0061% $ 26.4k | |
| Independent Director | 3.2yrs | US$339.98k | 0.0061% $ 26.4k | |
| Independent Director | 9.5yrs | US$352.48k | 0.013% $ 56.9k | |
| Member of Scientific Advisor | no data | Veri yok | Veri yok | |
| Director | 15.8yrs | US$354.98k | 6.4% $ 27.7m | |
| Member of Scientific Advisor | no data | Veri yok | Veri yok | |
| Independent Director | 6.5yrs | US$327.48k | 0.0061% $ 26.4k | |
| Lead Independent Director | 8.3yrs | US$334.98k | 0.0061% $ 26.4k | |
| Independent Director | 3.2yrs | US$324.98k | 0.0061% $ 26.4k | |
| Chairman | 15.7yrs | US$5.92m | 0.63% $ 2.7m | |
| Independent Director | 2.4yrs | US$329.98k | 0.0041% $ 17.6k |
7.4yrs
Ortalama Görev Süresi
69.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: RGNX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.4 yıldır).